Keliximab, CAS 174722-30-6

Product Description: Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Sharma A, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41./[2]Anderson D, et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol. 1997 Jul;84(1):73-84.

CAS Number: 174722-30-6

Molecular Weight: N/A

Compound Purity: 98.23

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Interleukin Related

• Artikelnummer: MEXHY-P99680-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99680-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated